Oxford Asset Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Oxford Asset Management’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-40,997	Closed	-$80K	–	1570
2016 Q4	$80K	Buy	+40,997	New	+$148K	﹤0.01%	738
2016 Q1	–	Sell	-3,404	Closed	-$99K	–	1004
2015 Q4	$99K	Buy	+3,404	New	+$103K	﹤0.01%	834

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Oxford Asset Management's PTX Position: Q1 2017 in Review

Oxford Asset Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2017, closing a stake of 40,997 shares — an estimated $80K sold.

Oxford Asset Management first reported a position in PTX in Q4 2015 and held it in 2 quarters. The position peaked at $99K in Q4 2015. 31 funds tracked by Wall St. Rank hold PTX as of Q1 2017.

Oxford Asset Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2017 after selling out during the quarter.
Oxford Asset Management sold 40,997 Pernix Therapeutics Holdings, Inc. shares in Q1 2017, an estimated $80K.
Oxford Asset Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2015 and held it in 2 quarters.
Oxford Asset Management's Pernix Therapeutics Holdings, Inc. position peaked at $99K in Q4 2015.
31 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2017.

Based on Oxford Asset Management's 13F filing for Q1 2017, filed 9 May 2017.